Soligenix Inc. is advancing its phase 2a clinical trial of SGX302, a synthetic hypericin therapy for mild-to-moderate psoriasis, building on promising phase 1/2 data. Early results from the trial show encouraging signs of safety and biological activity, highlighting SGX302's potential as a novel, well-tolerated treatment for a chronic autoimmune skin condition affecting millions globally. The company is leveraging its experience with hypericin-based therapies to address a significant market opportunity in dermatology, projected to reach $67 billion by 2030.
This expansion into psoriasis treatment represents a strategic move for Soligenix as it builds on its existing work with HyBryte (SGX301), another synthetic hypericin therapy being developed as a novel photodynamic therapy for cutaneous T-cell lymphoma. Ongoing trial results could pave the way for larger studies, regulatory guidance, and eventual commercialization. The company's development programs in its Specialized BioTherapeutics business segment also include expansion of its first-in-class innate defense regulator technology, dusquetide (SGX942) for the treatment of inflammatory diseases including oral mucositis in head and neck cancer, and SGX945 in Behçet's disease.
The advancement of SGX302 comes at a time when the global psoriasis treatment market continues to expand, driven by increasing prevalence of autoimmune conditions and demand for more effective, well-tolerated therapies. Soligenix's approach with synthetic hypericin represents a novel mechanism of action that could offer patients an alternative to existing treatments with potentially fewer side effects. The company maintains an active newsroom where investors can find the latest updates relating to SNGX available at https://ibn.fm/SNGX. Broader corporate information and development pipeline can be accessed through their official website at https://www.Soligenix.com.
